Press Releases



Date Title
11/08/18
Summary ToggleHistogenics Corporation Announces Third Quarter 2018 Financial and Operating Results WALTHAM, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- ‒ Histogenics and FDA Continue Discussions on NeoCart ® Phase 3 Data and Potential BLA Submission ‒ ‒ October 2018 Financing Expected to Provide Funding Into Middle of 2019 ‒ ‒ Histogenics to Host Conference Call and Webcast Today at 8:30 a.m.
11/01/18
Summary ToggleHistogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway WALTHAM, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on
10/25/18
Summary ToggleHistogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018 WALTHAM, Mass. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its third quarter 2018 financial results on November 8, 2018 ,
10/05/18
Summary ToggleHistogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants WALTHAM, Mass. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up
10/04/18
Summary ToggleHistogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants WALTHAM, Mass. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common
09/26/18
Summary ToggleHistogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway WALTHAM, Mass. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today announced that the U.S.
09/05/18
Summary ToggleHistogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage              ‒ Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After Treatment as Compared to Microfracture ‒              ‒ NeoCart Demonstrated Statistically Significant
08/09/18
Summary ToggleHistogenics Corporation Announces Second Quarter 2018 Financial and Operating Results ‒ Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Expansion of Management Team in Preparation for Potential Commercialization of NeoCart in 2020 ‒ ‒ Company to
07/31/18
Summary ToggleHistogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer Experienced Surgeon and Life Sciences Executive to Lead Medical Affairs, Clinical and Regulatory Operations in Preparation for Potential Commercial Launch of NeoCart® WALTHAM, Mass. , July 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the
07/26/18
Summary ToggleHistogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018 WALTHAM, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its second quarter 2018 financial results on August 9, 2018 ,
07/25/18
Summary ToggleHistogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference WALTHAM, Mass. , July 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley , Chief Executive Officer of Histogenics ,
07/23/18
Summary ToggleHistogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee WALTHAM, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Stephen Kennedy, Executive Vice President & Chief
05/31/18
Summary ToggleHistogenics Corporation to Host Investor Day on June 19, 2018

WALTHAM, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Histogenics will host its first Investor Day on Tuesday, June 19, 2018 , in

05/10/18
Summary ToggleHistogenics Corporation Announces First Quarter 2018 Financial and Operating Results

‒ Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30

04/26/18
Summary ToggleHistogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018

WALTHAM, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its first quarter 2018 financial results on May 10, 2018 ,

04/18/18
Summary ToggleHistogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief
03/28/18
Summary ToggleHistogenics Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass. , March 28, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming
03/19/18
Summary ToggleHistogenics Corporation to Present at Needham & Company’s 17th Annual Healthcare Conference WALTHAM, Mass. , March 19, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley , Chief Executive Officer of Histogenics ,
03/15/18
Summary ToggleHistogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017 NeoCart ® Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensing Agreement with MEDINET Co. Ltd. Provides Important Source of Funding and Enables Development and Potential Commercialization in Japanese
03/02/18
Summary ToggleHistogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings WALTHAM, Mass. , March 02, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced today that it will be exhibiting at the American Academy of
03/01/18
Summary ToggleHistogenics Corporation to Report 2017 Financial Results on March 15, 2018 WALTHAM, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report financial results for the quarter and year ended December 31,
02/20/18
Summary ToggleHistogenics Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming
01/25/18
Summary ToggleHistogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares WALTHAM, Mass. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten registered direct offering of 2,691,494 shares of its common
01/22/18
Summary ToggleHistogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock WALTHAM, Mass. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten registered direct offering of 2,340,430 shares of its common stock at a price of $2.35
01/09/18
Summary ToggleHistogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement WALTHAM, Mass. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that it has received the $10 million up-front payment from